Article Information
History
- March 30, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Stijntje W. Dijk, MD, MSc1,
- Eline Krijkamp, MSc1,
- Natalia Kunst, PhD2,3,
- Cary P. Gross, MD3,
- John B. Wong, MD4 and
- M.G. Myriam Hunink, MD, PhD*,1,5,6
- 1Department of Epidemiology and Department of Radiology, Erasmus University Medical Center, Rotterdam, The Netherlands
- 2Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, Boston, USA
- 3Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University School of Medicine, New Haven, CT, USA
- 4Division of Clinical Decision Making, Tufts Medical Center, Boston, USA
- 5Netherlands Institute for Health Sciences, Erasmus University Medical Center, Rotterdam, The Netherlands
- 6Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, USA
- ↵*Corresponding author contact
M.G. Myriam Hunink, Department of Epidemiology Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands (m.hunink{at}erasmusmc.nl), Telephone +31107043488, Fax +31107044657
Posted March 30, 2022.
Emerging Therapies for COVID-19: the value of information from more clinical trials
